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www.cdatm.orgAbstractObjective: Management of Graves' orbitopathy (GO) continues to be a challenge to clinical endocrinologists. In the last few years,
surveys on GOmanagement have succeeded in elucidating trends in Europe and Latin America. To determine how endocrinologists
in China assess and treat patients with GO and gain insight into how to make the management of this disease more uniform and
standardized.
Methods: Based on the questionnaire used in the European survey on GO, a questionnaire in China was drafted and circulated to
the members of Chinese Society of Endocrinology (CSE) during the annual meeting.
Results: A total of 124 valid responses were analysed. Almost all respondents (94.4%) claimed that a multidisciplinary
approach for GO management was valuable. Over 80% of the participants advocated the assessment of exophthalmometry,
vision, visual fields by perimetry, eye movements, and fundoscopy. Glucocorticoids were preferred as the first-line therapy by
92.7% of respondents, among them, 59.7% choose the intravenous route. The treatment strategy for GO with intravenous
glucocorticoids therapy still remains debatable. Anti-thyroid drugs (ATDs) were the most common choice (72.6%) for first-line
therapy of coexisting hyperthyroidism. Treatment options for GO were very similar among Chinese, Latin-American and Eu-
ropean respondents, whereas radioactive iodine and surgical treatment were more often indicated for co-existing hyperthyroidism
in China.* Corresponding author. 1 Huadian Road, Nanjing, 210028, China. Tel.: þ86 13337806688.
E-mail address: liuchao@nfmcn.com (C. Liu).
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118 S.-H. Xu et al. / Chronic Diseases and Translational Medicine 1 (2015) 117e123Conclusion: The appropriate treatment for patients with GO is controversial even among thyroid specialists. Further training of
thyroid specialists, easier access of patients to multidisciplinary centres and establishment of practice guidelines are required for the
management of this condition in China.
© 2015 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Graves' orbitopathy; Thyrotoxicosis; Questionnaire surveyTable 1
Index case: patient with moderate to severe GO and hyperthyroidism.
Index case
A 65-year-old female patient presents with typical symptoms of
hyperthyroidism. She also gives a 6-week history of uncomfortable
watery eyes; lid swelling in the mornings and double vision on
upward and lateral gaze. She smokes 15e20 cigarettes per day. On
examination, she is found to be moderately thyrotoxic. She has an
easily palpable but small symmetrical goitre. There is marked
periorbital edema, redness of the conjunctivae, bilateral chemosis
and obvious restriction of eye movements on upward gaze, and
attempts to look up provoke retro-orbital pain. Proptosis is 19 mm
bilaterally. Her visual acuity is normal (6/6e1.0, bilaterally on the
Snellen chart). On direct questioning, she admits to being aware
that colors appear less bright than they did two weeks earlier.
Fundoscopy shows normal optic disks. Biochemistry confirms
thyrotoxicosis (free thyroxine 52 pmol/L, normal range 11e23;
total tri-iodothyronine 9.3 nmol/L, normal range 1e2.9; thyroid-
stimulating hormone (0.05 mU/L).
GO: Graves' orbitopathy.Introduction
Graves' orbitopathy (GO), a comorbidity of Graves'
disease, remains a challenge for clinical endocrinolo-
gists. The prognosis is usually unfavorable and it re-
quires multidisciplinary collaborations of radiologists,
ophthalmologists and surgeons. The prevalence of GO
is approximately 0.25% in the general population, and
about 30e50% of Graves' patients have clinically
apparent ophthalmopathy.1 GO patients are also at high
risks of sick leaves, permanent work disability and
early retirement. It was reported that direct costs per
year were higher in sight-threatening GO than in
moderate-to-severe or mild GO.2 Therefore, early
diagnosis and intervention of GO is essential not only
from the public health perspective, but also from an
economic one.
The most appropriate approach to treat GO is not
been identified yet and using glucocorticoids for
treating the severe forms of GO remains controversial.
The European Group on Graves' Orbitopathy
(EUGOGO) and the Latin American Thyroid Society
(LATS) conducted questionnaire surveys targeting
their members. They found big differences among
thyroid experts in treating GO.3,4 Glucocorticoids were
recommended by most respondents, but the ways of
using glucocorticoids (orally or intravenously, alone or
in combination with other treatments) differ from each
other substantially. Moreover, potential problems in the
diagnosis and management of GO and coexisting hy-
perthyroidism were identified in these studies.
The present study aims to investigate the current
status of GO evaluation and treatment among Chinese
endocrinologists and compare with Latin American
and European.
Materials and methods
Based on the questionnaire used in the European
survey on GO, a questionnaire in Chinese was draftedand circulated among members of Chinese Society of
Endocrinology (CSE) during the 11th Annual Meeting
of CSE in Guangzhou, China, 2012.
There are two parts and 18 questions in the ques-
tionnaire. In the first part, all participants were asked to
give their general impressions on GO in their daily
practice. The second part is about a description of an
index case (Table 1). Questions related to the index
case were asked, with the focus on GO diagnosis and
treatment; specifically steroids usage and management
of co-existing hyperthyroidism (Table 2).
Data were typed into a computer operated database
(Microsoft Excel 2010; Microsoft, Atlanta, USA) and
analysed using Graphpad Prism5 software (GraphPad
Software Inc., San Diego, USA). Results were pre-
dominantly given as frequencies, and c2 tests were
used to compare among China, Europe and Latin
America. A P value <0.05 was considered statistically
significant.
Table 2
Percentages of responders who suggested different tests for the index
patient with GO (n ¼ 124).
%
Exophthalmometry 98.4
TSH receptor antibodies 96.8
Thyroid function 96.8
Visual acuity 94.4
Visual fields by perimetry 91.9
Eye movement 89.5
Fundoscopy 88.7
Thyroid ultrasonography 87.9
Ophthalmic ultrasonography 74.2
Eye muscle antibodies 73.4
Corneal evaluation 62.9
Measurement of palpebral fissure 53.2
CT scan 53.2
Magnetic resonance imaging 50.8
Plasma plus urinary glycosaminoglycans 46.0
Color vision 42.7
Radiolabelled-octreotide scintigraphy 27.4
GO: Graves' orbitopathy; TSH: thyroid-stimulating hormone.
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Fig. 1. Initiation treatment choices for index case at index patient's
first presentation.
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General information
Questionnaires from 149 respondents were retrieved
from 300 distributions. Questionnaires with missing
information were excluded (n ¼ 25), leaving a total of
124 for analysis. The overall response rate was 41.3%,
significantly higher than that of surveys conducted in
Europe in 2006 (22.8%)3 and in Latin America in 2008
(33.8%).4
There were 11 respondents who met with more than
500 patients with Graves' disease during previous six
months of the survey, whereas there were only nine
who saw fewer than 10 cases. Overall, two and seven
respondents treated at least 100 and 50e99 GO cases,
respectively, whereas the majority (92.7%) treated
fewer than 50 cases. More than half of the respondents
(53.2%) thought the GO prevalence were ‘increasing’
or ‘unchanged’. Almost all respondents (94.4%)
claimed that it was highly desirable to treat GO in a
multidisciplinary approach, as well as to establish
clinical guidelines for the management of the disease.
Assessment and diagnosis of GO
The index patient was featured in the case report
with a history of colour desaturation, but with normal
visual acuity (Table 1). The majority of respondents
(85.4%) replied that they would treat her in an out-patient clinic, while only 10.3% replied that the pa-
tient should be hospitalized in the Endocrinology
Department. The remaining four respondents would
have the patient referred to an ophthalmologist.
Tests were listed as possible choices for diagnosis
(Table 2). All participants opted to use at least two
diagnostic tests. Beside thyroid function, exoph-
thalmometry (98.4%), thyroid-stimulating hormone
(TSH) receptor antibodies (96.8%), visual acuity
(94.4%), visual fields by perimetry (91.9%), eye
movement (89.5%), fundoscopy (88.7%) and thyroid
ultrasonography (87.9%) were the most commonly
selected tests. About half of the respondents recom-
mended computed tomography scans (CT scans,
53.2%) as well as magnetic resonance imaging (MRI,
50.8%), and only 27.4% preferred radiolabelled-
octreotide scintigraphy. Suggestions for further inves-
tigation varied among respondents.
Treatment of GO
As the initial treatment, both general (avoid corneal
exposure, wear protective glasses, etc.) (96.8%) and
specific approaches (quit smoking) (92.7%) were rec-
ommended by the vast majority of respondents. In
addition, diuretics were suggested by 48.4%.
The percentages of respondents who selected
different therapeutic approaches for moderate or severe
GO are shown in Fig. 1. Glucocorticoids were rec-
ommended by 92.8% of respondents, either alone or
combined with radiotherapy, decompressive surgery,
Table 3
A comparison of treatment options for GO and hyperthyroidism
among Chinese, European and Latin-American surveys.
Items China Europe Latin-America
Total number of responders 124 108 102
Treatment for GO
Steroids (%) 92.7 90.5 88.2
Orbital irradiation (%) 16.1 23.8 17
Surgery (%) 7.3 20.9 7
Treatment for comorbid thyrotoxicosis
ATDs (%) 72.6 90.9** 86.2*
Radioiodine (%) 16.1 2** 5.9*
Surgery (%) 9.7 3 0**
GO: Graves' orbitopathy; ATDs:antithyroid drugs.
Compared to China, *P < 0.05, **P < 0.01.
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glucocorticoid therapy alone, while only 18.3% and
10.4% chose combined therapies with somatostatin and
other immunosuppressors, respectively. The preferred
route of administration for steroids was intravenous
(59.7%), followed by oral administration (23%) and a
combination of both (13.7%), plus uncertain from four
respondents.
For intravenous methylprednisolone treatment, four
different therapeutic approaches commonly seen in the
literature5 were provided in this survey1: 12-week
course, 0.5 g/week intravenous methylprednisolone
for six consecutive weeks followed by 0.25 g/week for
six weeks2; 3-day course, 0.5e1 g/d intravenous
methylprednisolone for three consecutive days, fol-
lowed by tapering dose of oral prednisolone3; 8-week
course, four cycles 15 mg/kg intravenous methylpred-
nisolone biweekly (bw), then four cycles 7.5 mg/kg
intravenous methylprednisolone bw4; 6-week course,
0.5e1 g/d intravenous methylprednisolone for 3e5
consecutive days repeated once weekly over five
weeks. Among those respondents preferring intrave-
nous glucocorticoid treatment, 50.4%, 37.8% and
16.2% chose the 1st, 2nd and 4th approaches, respec-
tively. Only one respondent opted for the 3rd option,
while five had other terms without enough details
mentioned.
In light of serious adverse events including Cushing's
Syndrome, osteoporosis as well as potential cardiovas-
cular and hepatic risks, the dose and duration of oral and
intravenous glucocorticoid treatment should be decided
carefully by all endocrinologists. Overall, 32.3% and
49.2% of respondents recommended total durations of
glucocorticoid therapy within 1e3 months and 3e6
months, respectively. The dose of glucocorticoids, either
initially or during the entire treatment, was also recor-
ded by the respondents. Of those initiating oral gluco-
corticoids as the first-line therapy (n ¼ 29), 18
respondents chose a dose range of 10e30 mg prednis-
olone (or equivalent), while eight chose >30e60 mg
and three chose >60 mg. For intravenous methylpred-
nisolone, 40.3% respondents recommended a cumula-
tive dose of less than 8 g in a single course, while
14.5%, 20.2%, and 5.6% recommended <5 g, <12 g,
and <16 g, respectively. Among other immunosup-
pressive agents to be used in case of unsatisfactory ef-
ficacy or severe side effects of glucocorticoid therapy,
cyclophosphamide and cyclosporine A were each rec-
ommended by 50.8% and 36.3% of respondents,
respectively. Others included intravenous immunoglob-
ulins (11.3%), tacrolimus (2.4%), and mycophenolate
mofetil (10.5%).Treatment of co-existing hyperthyroidism
Anti-thyroid drugs (ATDs) were the most predom-
inant choice (72.6%) as the first-line therapy for co-
existing hyperthyroidism in the above case. Radio-
iodine was chosen only by 16.1%, and surgery by
9.7%. If surgery was being planed, 55.6% would pre-
scribe prophylactic corticosteroids. Of these partici-
pants, 63.7% recommended prednisolone 20e40 mg
(or equivalent). Half of the respondents replied that
thyroid surgeries should be determined by surgeons,
whereas 37.1% chose near total thyroidectomy as their
initial treatment because recurrence of hyperthyroid-
ism would not be seen. If radioiodine was recom-
mended to the patient in this case, prophylactic
glucocorticoids were suggested by the majority
(64.7%), whereas they were opposed by 7.3%. The
appropriate dose of glucocorticoids remains contro-
versial: 31.5% preferred <30 mg prednisolone (or
equivalent), 27.4% preferred 30e100 mg, and 4.8%
preferred >100 mg. Other respondents recommended
postoperative use of glucocorticoids.
Compared to the European and Latin-American
surveys
Compared to European3 and Latin-American4 sur-
veys, choices for the treatment of GO were very similar.
There were no significant differences of glucocorticoid
use, orbital irradiation, and decompressive surgery be-
tween our survey and theirs (Table 3). Orbital irradia-
tion and decompressive surgery in Europe were more
often indicated for the case patient than they were in
China (23.8% vs. 16.1%, P > 0.05) and Latin-America
(23.8% vs. 17.0%, P > 0.05). By contrast, discrepancies
exist in treatment preferences of hyperthyroidism
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frequently recommended by Chinese respondents than
by European (72.6% vs. 90.9%, P < 0.01) and Latin-
American respondents (72.6% vs. 86.2%, P < 0.05).
Chinese respondents were more likely to use radio-
iodine than European (16.1% vs. 2.0%, P < 0.01) and
Latin-American respondents (16.1% vs. 5.9%,
P < 0.05), as well as thyroidectomy (9.7% in China vs.
3.0% in Europe, P > 0.05 and 9.7% in China vs. 0% in
Latin-America, P < 0.01).
Discussion
GO is an autoimmune process and very common
extra-thyroidal manifestation of Graves' disease. So far,
its etiology remains enigmatic. Optimal therapeutic
choices for both GO and Graves' disease are still
controversial among endocrinologists, radiologists,
ophthalmologists and surgeons. Mild GO may improve
spontaneously and only require general measures to
control symptoms, whereas moderate to severe GO
will require medical treatment.6 More importantly,
patients with GO often suffer from psychological
problems which are important determinants of quality
of life, particularly during the early days after the
diagnosis.7 Early diagnosis, accurate assessment and
timely treatment are essential to improving the
outcome. Internationally accepted consensus or
guidelines for GO management are still lacking,
especially in China. Several previous surveys have
elucidated and addressed controversies regarding the
management of GO and coexisting hyperthyroidism in
Europe and Latin-America. Therefore, we herein
conducted a questionnaire survey targeting members of
CSE in China. As we anticipated, the overwhelming
majority of respondents would welcome the publica-
tion of practice guidelines for GO management.
A case of a 65-year-old female patient was used in
the survey. Her visual acuity was normal and fundo-
scopy showed normal optic disks. However, she com-
plained that colours appeared less bright than before,
which indicated that she was probably having early
optic nerve compression.3 Almost two thirds of Euro-
pean respondents would urgently refer this GO patient
to an ophthalmologist because of the symptoms.3 On
the contrary, the vast majority of Chinese endocrinol-
ogists in the present survey replied that the patient
should be further investigated by hospitalization, while
only a few respondents would refer her to an
ophthalmologist during her first visit. Most likely, this
significant difference is due to the fact that most Chi-
nese endocrinologists would consider consulting anophthalmologist while the patient is hospitalized. The
other explanation could be that some respondents may
lack the recognition of the disease seriousness.
For patients with mild GO, selenium administration
significantly improved quality of life, reduced ocular
involvement, and slowed disease progression.8 Mod-
erate to severe GO can be effectively treated with
glucocorticoids, orbital irradiation, or both. High-dose
intravenous glucocorticoids should be immediately
administered to patients with optic neuropathy.9 This is
likely to be well accepted by endocrinologists from
Europe and Latin-America as well as from China.
More than 70% of respondents chose intravenous
glucocorticoids as the first-line therapy for the patient.
The duration and dose of glucocorticoid treatment
have always been contentious. Zang et al5 in 2011
identified all randomized and uncontrolled trials,
consensus statement, systematic reviews, and meta-
analyses to investigate the efficacy and adverse effects
of intravenous glucocorticoids therapy in GO. They
found that the current first-line treatment for active,
moderate-to-severe GO was a 12-week course of high-
dose intravenous glucocorticoid pulses. When
compared with the oral glucocorticoid group, patients in
the 12-week intravenous glucocorticoid group had a
higher treatment response at three months (72% vs. 49%,
P< 0.001).10 Overall, the response rate of this regimen is
approximately 80%.5 The efficacy of the regimen is also
well recognized by nearly half of the respondents in our
study. Meanwhile, more than one third chose the second
3-day course approach in the questionnaire. Indeed,
improvement of soft tissue swelling and ocular motility
was observed in only 29% patients.11 More than a half of
the participants replied that the cumulative dose should
not exceed 8 g in one single course, which was also
strongly recommended by Zang et al. Intravenous glu-
cocorticoids have been thought to have a statistically
significant advantage over oral treatment and cause
significantly fewer adverse events.12,13 Recently, a
questionnaire survey among members of the European
Thyroid Association revealed that glucocorticoids were
preferentially administered intravenous for the treatment
of GO in Europe, but daily or alternate day intravenous
glucocorticoids were also associated with severe adverse
effects more frequently, including fatal cases.14 Further
training is required for clinicians on the standardized use
of glucocorticoids for the management of GO.
An association between radioiodine therapy for
hyperthyroidism and GO was found recently. Radio-
iodine therapy for hyperthyroidism was followed by
statistically significant increases in the ocular mani-
festations of GD when compared with surgical
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radioiodine is considered as the first-line treatment for
Graves' Disease in many institutions, particularly in the
United States. In the present survey, the proportion of
Chinese respondents preferring radioiodine therapy for
hyperthyroidism in the case was significantly higher
than that of European and Latin-American. However,
some studies found that radioiodine therapy could
induce onset or progression of GO in approximately
15e20% patients,17 especially when they had a history
of cigarette smoking.18
Glucocorticoids prophylaxis is highly effective in
preventing deterioration of eye disease in patients with
pre-existing ophthalmopathy compared with radio-
iodine therapy without glucocorticoids.19 It was rec-
ommended by almost two thirds of Chinese
respondents in our study. Among them, however, the
recommended dose of prophylactic glucocorticoids
varied significantly. Lai et al20 demonstrated that lower
doses of oral prednisone (about 0.2 mg/kg bw or
0.3e0.5 mg/kg bw for 6-week) were effective to pre-
vent GO exacerbation without the adverse effects of
high-dose intravenous glucocorticoids.
Some limitations of the present study warrant dis-
cussion. The sample size is relatively small. Particu-
larly, we didn't collect information on clinical variables
in the questionnaire. The active or inactive phase of GO,
iatrogenic Cushing's Syndrome, diabetes and a younger
age may affect treatment choices of respondents. In
addition, the 124 responders who completed this ques-
tionnaire survey do not represent all Chinese endocri-
nologists. A comprehensive investigation of a large
sample of endocrinologists is required.
In conclusion, the results of this questionnaire sur-
vey confirmed that there is still no consensus regarding
to the optimal management of GO among CSE mem-
bers. A number of disagreements on GO management
exist among endocrinologists from Europe, Latin-
America, and China. The establishment of practice
guidelines for GO management is urgently needed.
Further training and education of thyroid specialists are
required for the management of the disease.
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